Steven Kho, Hasrini Rini, Noy N. Kambuaya, Syawal Satria, Freis Candrawati, Putu A. I. Shanti, King Alexander, Benediktus Andries, Aisah R. Amelia, Anjana Rai, Kim A. Piera, Agatha M. Puspitasari, Ristya Amalia, Pak Prayoga, Leo Leonardo, Maulina Hafidzah, Theo Situmorang, Dewi S. Margayani, Desandra A. Rahmayenti, Pengxing Cao, Enny Kenangalem, Leily Trianty, Damian Oyong, Julie A. Simpson, Rintis Noviyanti, Pierre A. Buffet, Jeanne R. Poespoprodjo, Nicholas M. Anstey
{"title":"Splenic Tropism and Spleen-Modulated Systemic Inflammation in Acute Plasmodium vivax Malaria","authors":"Steven Kho, Hasrini Rini, Noy N. Kambuaya, Syawal Satria, Freis Candrawati, Putu A. I. Shanti, King Alexander, Benediktus Andries, Aisah R. Amelia, Anjana Rai, Kim A. Piera, Agatha M. Puspitasari, Ristya Amalia, Pak Prayoga, Leo Leonardo, Maulina Hafidzah, Theo Situmorang, Dewi S. Margayani, Desandra A. Rahmayenti, Pengxing Cao, Enny Kenangalem, Leily Trianty, Damian Oyong, Julie A. Simpson, Rintis Noviyanti, Pierre A. Buffet, Jeanne R. Poespoprodjo, Nicholas M. Anstey","doi":"10.1002/ajh.70498","DOIUrl":"10.1002/ajh.70498","url":null,"abstract":"<p>In chronic <i>Plasmodium vivax</i> (Pv) infection, the spleen accounts for over 98% of total-body parasite biomass. Whether splenic tropism also occurs in acute infection and how the spleen influences pathogenesis have not been systematically explored. In Papua, Indonesia, we compared clinical and hematology data in 24 spleen-intact and 25 previously splenectomized patients with acute uncomplicated vivax malaria. Plasma levels of Pv lactate dehydrogenase (PvLDH) and markers of intravascular haemolysis, inflammation, endothelial activation and neutrophil activation were measured by ELISA. Circulating parasitaemia was four times higher in splenectomized compared to spleen-intact patients but total-body Pv biomass (PvLDH) was three times lower in patients without a spleen. Parasite staging and greater organ-specific symptoms suggest parasite redistribution in the absence of a spleen. Linear regression modeling adjusting for circulating parasitaemia, age, sex and fever duration demonstrated an 8.1-fold higher PvLDH concentration in spleen-intact patients, indicating a splenic biomass accounting for 89% of total-body parasites. Giemsa-based splenic histology in an untreated patient splenectomized during acute vivax malaria revealed a spleen-to-blood biomass ratio of 10.7. In spleen-intact patients, splenic biomass correlated strongly with markers of disease intensity, endothelial activation and systemic inflammation, whereas circulating parasitaemia correlated weakly or not at all. Compared to spleen-intact patients, cell-free hemoglobin, endothelial activation and systemic inflammation were higher in splenectomized patients while inflammasome-dependent responses were lower. In conclusion, Pv is predominantly an infection of the spleen in acute clinical vivax malaria. While the size of this hidden population correlates with disease intensity, the spleen likely modulates inflammatory pathways and heme-associated pathology.</p>","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":"101 12","pages":"2976-2989"},"PeriodicalIF":9.4,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ajh.70498","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148922944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Response to “Undetectable Hydroxyurea in an Untimed Blood Sample Does Not Establish Nonadherence”","authors":"Sigrid van der Veen, Eduard J. van Beers","doi":"10.1002/ajh.70515","DOIUrl":"10.1002/ajh.70515","url":null,"abstract":"<p>We thank Zhao and Shen for their thoughtful comments regarding our recent publication and appreciate the opportunity to further discuss the interpretation and potential clinical implications of our findings [<span>1, 2</span>].</p><p>We agree that hydroxyurea (HU) detectability by direct-infusion high-resolution mass spectrometry (DI-HRMS) should not be interpreted in isolation. As acknowledged in our original publication, the absence of a detectable HU signal in a dried blood spot cannot by itself establish nonadherence, inadequate dosing, or treatment failure. Factors such as dose timing, pharmacokinetic variability, and individual patient characteristics may all influence HU detectability [<span>3-5</span>]. We would like to clarify that the primary objective of our study was not to diagnose nonadherence at the individual patient level, but rather to evaluate HU exposure in relation to treatment response in a large real-world European cohort.</p><p>We also agree that further validation studies are needed. Studies incorporating precise dosing and sampling times, repeated measurements, and targeted quantitative assays would provide important additional insight into the relationship between HU exposure, DI-HRMS detectability, and treatment response.</p><p>Importantly, our study aimed to evaluate HU exposure under real-world conditions rather than under controlled trial settings. While this approach introduces additional sources of variability, it also reflects routine clinical practice, where treatment adherence, dose timing, and treatment response are inherently heterogeneous. We believe this real-world perspective provides complementary insights into challenges affecting HU treatment exposure and response that may be less apparent in highly controlled study environments.</p><p>However, we would like to emphasize that our conclusions were not based solely on the presence or absence of a detectable HU signal. Rather, our interpretation was guided by the observation that patients with low or undetectable HU signals generally exhibited less pronounced hematological and cytotoxic treatment responses than patients with detectable HU. We therefore propose that HU detectability may provide complementary information regarding recent treatment exposure when interpreted alongside established markers of HU response.</p><p>Regarding the pediatric findings, we agree that interpretation is particularly challenging in younger children. Baseline HbF levels are higher in childhood, especially in children younger than 10 years of age, potentially reducing observable differences attributable to HU treatment. In addition, age-related pharmacokinetic variation may influence HU detectability [<span>3-5</span>]. These factors may have contributed to the limited differences observed between children with and without detectable HU, whereas differences were generally more pronounced among patients older than 10 years.</p><p>We fully agree that a negative DI-HRMS signa","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":"101 12","pages":"3077-3078"},"PeriodicalIF":9.4,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ajh.70515","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149079445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Eloïse Laouenan, Brigitte Pan-Petesch, Karine Morcel, Claire de Moreuil, Emmanuelle Courtois-Communier, Marie-Antoinette Sevestre, Sara Robin, François Anouilh, Cécile Tromeur, Christophe Leroyer, Francis Couturaud, Emmanuelle Le Moigne
{"title":"Superficial Vein Thrombosis During Pregnancy and Postpartum—Findings From the French Multicenter Cohort “HEMOTHEPP” Study","authors":"Eloïse Laouenan, Brigitte Pan-Petesch, Karine Morcel, Claire de Moreuil, Emmanuelle Courtois-Communier, Marie-Antoinette Sevestre, Sara Robin, François Anouilh, Cécile Tromeur, Christophe Leroyer, Francis Couturaud, Emmanuelle Le Moigne","doi":"10.1002/ajh.70503","DOIUrl":"10.1002/ajh.70503","url":null,"abstract":"<p>Superficial vein thrombosis (SVT), previously considered a benign entity, is now recognized as part of the venous thromboembolism (VTE) continuum [<span>1-5</span>]. This shift is particularly relevant in the obstetric context, a prothrombotic state in which the epidemiology and prognostic significance of SVT remain insufficiently characterized. Although VTE risk increases during pregnancy and postpartum [<span>6, 7</span>], data on obstetric SVT remain sparse and mostly derive from healthcare databases. In a Danish retrospective nationwide study, the incidence of pregnancy-associated SVT was 0.6 per 1000 person-years, and the subsequent VTE risk within the same pregnancy reached 13.0% among women with SVT [<span>8</span>]. Despite limited evidence, American Society of Hematology guidelines suggest anticoagulation in pregnancy-associated SVT, based on extrapolated evidence from nonpregnant populations, with optimal management still undefined [<span>9</span>]. In addition, whether established pregnancy-specific VTE risk factors also predispose to obstetric SVT is unclear [<span>10-12</span>].</p><p>We analyzed data from a large French prospective cohort study originally designed to assess obstetric-related VTE to determine the incidence of symptomatic, documented isolated SVT, describe affected individuals, and assess recurrent SVT or VTE [<span>13</span>].</p><p>The HEMOTHEPP study (NCT02443610) is a French population-based multicenter prospective cohort study including 20 238 unselected pregnant persons at delivery and followed during 3 months postpartum, from June 2015 to January 2019 [<span>14</span>]. The main inclusion criteria were age ≥ 16 years and delivery > 15-week gestation.</p><p>The primary outcome was a symptomatic ultrasound-confirmed SVT of the lower limb, without concomitant deep vein thrombosis, during pregnancy or the postpartum period. Secondary outcomes were symptomatic ultrasound-confirmed SVT of the upper limb, symptomatic recurrent SVT [<span>15</span>], and symptomatic thrombotic recurrence, including calf muscular vein thrombosis, deep vein thrombosis, pulmonary embolism, or unusual site venous thrombosis during pregnancy or the postpartum period. After SVT diagnosis, imaging follow-up was not systematic, but compression ultrasonography was repeated when thrombus extension or recurrence was clinically suspected. All thrombotic events were confirmed by validated diagnostic tests and adjudicated by an independent critical events committee.</p><p>Data on demographics, previous SVT or VTE, comorbidities, pregnancy and delivery characteristics, and anticoagulant treatments were systematically recorded in an electronic case report form via structured interviews and medical record review during the maternity stay and at 3-month postpartum. Anticoagulant treatment duration was available in days for persons who developed SVT or VTE (Figures S1 and S2) and by period (i.e., pregnancy and/or postpartum) for other participants.","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":"101 12","pages":"3059-3066"},"PeriodicalIF":9.4,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ajh.70503","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149009891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Could Mixed CAR T-Cell Products and Overlapping Patients Overestimate the Risk of HLH With Tisagenlecleucel?","authors":"Wenqiang Chen, Qiuhong Ma, Zhenzhen Chen","doi":"10.1002/ajh.70493","DOIUrl":"10.1002/ajh.70493","url":null,"abstract":"<p>We read with interest the systematic review and meta-analysis by Zhang et al. on hemophagocytic lymphohistiocytosis (HLH) and immune effector cell-associated HLH-like syndrome after CAR T-cell therapy. The authors reported that patients with B-cell acute lymphoblastic leukemia (B-ALL) and recipients of tisagenlecleucel had the highest risk. They further concluded that disease type and the specific CAR T-cell product were the main drivers of HLH risk [<span>1</span>]. These findings may guide risk classification and clinical monitoring. However, review of the original studies raises concerns about product classification and patient independence in a key cohort. These concerns may affect the main conclusions rather than only the exact numerical estimates.</p><p>Maron et al. included 38 patients and 39 first CAR T-cell infusions. Only 19 infusions used tisagenlecleucel, whereas 20 used an institutional investigational CD19/4-1BB product. One patient received both products, and the cohort also included one patient with B-lymphoblastic lymphoma [<span>2</span>]. The study reported five cases of CAR T-cell associated HLH in the mixed cohort but did not report which product was used in each case. Zhang et al. nevertheless classified all 5 events and all 39 infusions as tisagenlecleucel-treated B-ALL, although their eligibility criteria were limited to approved products and stated that studies with multiple products would be divided into separate cohorts [<span>1</span>].</p><p>This classification may directly change the results. If any of the five events occurred after the investigational product, the number of tisagenlecleucel-related events was overestimated. At the same time, including 20 non-tisagenlecleucel infusions in the denominator means that 5/39 cannot be interpreted as a product-specific rate for either product. These five events accounted for 31.3% of all tisagenlecleucel HLH events and 50% of all B-ALL events in the meta-analysis. After removing this cohort, the simple event proportion would decrease from 16/391 to 11/352 for tisagenlecleucel and from 10/145 to 5/106 for B-ALL. These calculations do not replace the authors' random-effects analysis, but they show that the reported rates of 4.3% and 6.9%, and possibly the ranking of the highest-risk groups, depend strongly on this single cohort. If the corrected subgroup difference is no longer significant, the conclusion that a specific CAR T-cell product is a main driver of HLH risk would also require revision.</p><p>Possible patient overlap may further increase this bias. Maron et al. stated that clinical outcomes for a subset of patients had been reported elsewhere and cited Ravich et al. [<span>2, 3</span>] Ravich et al. included 31 patients treated with tisagenlecleucel at Johns Hopkins and St. Jude between March 2018 and November 2020, which overlaps with the center and study period of the Maron cohort [<span>3</span>]. If the two HLH cases reported by Ravich et al. were included a","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":"101 12","pages":"3052-3053"},"PeriodicalIF":9.4,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ajh.70493","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148962769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Amber Afzal, Luo Suhong, Amir Mahmoud, Brian F. Gage, Kristen M. Sanfilippo
{"title":"Anticoagulant Therapy and Bleeding-Related Hospitalizations in Patients With Cancer: A National Cohort Study","authors":"Amber Afzal, Luo Suhong, Amir Mahmoud, Brian F. Gage, Kristen M. Sanfilippo","doi":"10.1002/ajh.70491","DOIUrl":"10.1002/ajh.70491","url":null,"abstract":"<p>Retrospective cohort study of US veterans reporting rates of bleeding-related hospitalizations associated with anticoagulant therapy in patients with cancer.\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure>\u0000 </p>","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":"101 12","pages":"3047-3051"},"PeriodicalIF":9.4,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ajh.70491","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148902026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Victor Bobée, Stéphane Moutereau, Maïssa Souissi, Pierre Lebreton, Loïc Garcon
{"title":"Basophilic Stippling Unmasks Pyrimidine 5′-Nucleotidase Deficiency in a G6PD-Deficient Patient","authors":"Victor Bobée, Stéphane Moutereau, Maïssa Souissi, Pierre Lebreton, Loïc Garcon","doi":"10.1002/ajh.70495","DOIUrl":"10.1002/ajh.70495","url":null,"abstract":"<p>A 30-year-old man was referred to the hematology department for evaluation of chronic hemolytic anemia. His medical history included glucose-6-phosphate dehydrogenase (G6PD) deficiency, diagnosed during childhood following an episode of acute anemia that required red blood cell transfusion, and the ongoing hemolysis had long been attributed to this known enzymatic defect. No neonatal jaundice was reported. However, the patient described life-long jaundice and intermittent episodes of dark urine, without dyspnea. Physical examination showed splenomegaly. Initial blood tests showed moderate macrocytic anemia (hemoglobin 100 g/L, MCV 101 fL) with marked reticulocytosis (283 × 10<sup>9</sup>/L). Biochemical evidence of hemolysis included undetectable haptoglobin, elevated LDH (1064 IU/L), and total bilirubin of 66 μmol/L. Peripheral blood smear examination revealed polychromasia and numerous basophilic stipplings (Figure 1A,B). A supravital stain with brilliant cresyl blue demonstrated Heinz bodies within erythrocytes, indicating oxidized and denatured hemoglobin (Figure 1C). To further investigate the chronic hemolysis, a comprehensive workup was conducted, including the eosin-5-maleimide binding test, ektacytometry, hemoglobin electrophoresis, direct antiglobulin test, and assays for G6PD and pyruvate kinase activity. All results were normal except for markedly decreased G6PD activity, consistent with the known deficiency. Due to the presence of prominent basophilic stippling, additional erythrocyte enzyme assays were performed and pyrimidine 5′-nucleotidase (P5N) activity was profoundly reduced (< 1 IU/g Hb, normal range 5.6–9.0), while glucose phosphate isomerase (GPI), triosephosphate isomerase (TPI), and hexokinase (HK) levels were normal. These findings led to the diagnosis of P5N deficiency in addition to the pre-existing G6PD deficiency. Folic acid supplementation was initiated, and the patient was enrolled in long-term follow-up every 3 years to monitor for potential iron overload.</p><p>Patients with G6PD deficiency are typically asymptomatic between hemolytic episodes, except in rare cases involving class A variants according to the WHO classification [<span>1</span>]. Heinz bodies, representing denatured oxidized hemoglobin, are classically observed in G6PD deficiency and in unstable hemoglobinopathies. Unlike G6PD, P5N is an enzyme involved in the degradation of pyrimidine nucleotides. Its deficiency is a rare congenital enzymopathy that leads to the accumulation of pyrimidine derivatives in erythrocytes, forming insoluble aggregates responsible for basophilic stippling and resulting in chronic hemolytic anemia [<span>2</span>]. While basophilic stippling is not specific to P5N deficiency and may also be seen in conditions such as lead poisoning or myelodysplastic syndromes, it remains a hallmark feature that can strongly suggest the diagnosis. In this case, the unusually dense and widespread basophilic inclusions prompted further","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":"101 12","pages":"3032-3033"},"PeriodicalIF":9.4,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ajh.70495","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148915495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Overall Survival Benefit and Long-Term Safety of Romiplostim in Persistent Chemotherapy-Induced Thrombocytopenia","authors":"Andrew B. Song, Gerald A. Soff","doi":"10.1002/ajh.70510","DOIUrl":"10.1002/ajh.70510","url":null,"abstract":"<p>Chemotherapy-induced cytopenias are among the most common adverse effects of cytotoxic cancer therapy and frequently lead to treatment delays or dose reductions, resulting in reduced relative dose intensity (RDI) [<span>1-4</span>]. Granulocyte colony-stimulating factor (G-CSF) and related agents are widely used and are standard practice for treatment and prevention of chemotherapy-induced neutropenia [<span>2, 5</span>] In contrast, erythropoiesis-stimulating agents (ESA) are generally not used to treat anemia in patients receiving curative intent chemotherapy because of evidence of increased thromboembolism, tumor progression/recurrence, and decreased overall survival [<span>6</span>]. Development of effective treatment for chemotherapy induced thrombocytopenia (CIT) has been considerably slower and remains an unmet need [<span>1, 3</span>].</p><p>Severe CIT may increase the risk of bleeding, but the major consequence is the common practice of chemotherapy dose reduction and/or delay to avoid the development of severe CIT [<span>1, 7</span>]. In retrospective studies, reduced relative dose intensity (RDI) of chemotherapy, from all causes, has been associated with reduced progression-free/disease-free and overall survival across multiple malignancies, including adjuvant and neoadjuvant breast cancer, aggressive B-cell lymphoma, colon cancer, and non–small cell lung cancer, among others [<span>1, 2, 8, 9</span>]. Importantly, these past studies did not specifically analyze reduced RDI from CIT.</p><p>To date, there are no agents approved by the US Food and Drug Administration (FDA) for treatment or prevention of CIT. Recombinant human IL-11 (oprelvekin) was poorly tolerated, with modest overall benefit relative to toxicity, and was voluntarily withdrawn from the market [<span>3</span>]. Early development of recombinant thrombopoietin (TPO), also referred to as human megakaryocyte growth and development factor (rHuMGDF), was in a pegylated form. Administration of PEG-rHuMGDF induced cross-reactive antibodies capable of neutralizing endogenous TPO and causing worsening thrombocytopenia in some patients [<span>10</span>]. Due to sequence homology, development of both PEG-rHuMGDF and recombinant human TPO was halted although rhTPO is approved and widely used in China [<span>4</span>].</p><p>The second-generation thrombopoiesis agents, the thrombopoietin receptor agonists (TPO-RAs), include romiplostim, eltrombopag, avatrombopag, lusutrombopag, and hetrombopag. TPO-RAs lack sequence homology with native thrombopoietin and are FDA approved for several thrombocytopenic disorders, including immune thrombocytopenia, aplastic anemia, thrombocytopenia associated with chronic liver disease, and others [<span>11</span>]. The TPO-RAs are currently the primary agents being studied for CIT.</p><p>Studies of TPO-RAs for CIT have shown mixed results. One major reason is the heterogeneous patient populations studied. Early investigations in CIT primarily evaluat","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":"101 12","pages":"2957-2960"},"PeriodicalIF":9.4,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ajh.70510","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149069073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Ferritin Alone Is Not Sufficient to Diagnose Iron Deficiency in Patients With Anemia due to Chronic Disease","authors":"B. S. Skikne, P. C. Southwick","doi":"10.1002/ajh.70511","DOIUrl":"10.1002/ajh.70511","url":null,"abstract":"<p>Ferritin has been used as a laboratory test for over 50 years. In clinical practice, ferritin cutoff levels at the lower end are typically 15–30 ng/mL, with the upper limit up to 200 ng/mL [<span>1</span>]. As is well known, a diagnostic dilemma is often encountered in diagnosing concurrent iron deficiency in patients with anemia of chronic disease (ACD). Serum ferritin is affected by the acute phase response associated with acute and or chronic inflammation [<span>2</span>]. This frequently leads to a dissociation of serum ferritin and iron status, with ferritin values often normal to raised in spite of depleted iron stores or negative iron balance with tissue iron deficiency.</p><p>The goal of the serum transferrin receptor (TfR) index (TfR/log ferritin) is in part to enhance detection of coexisting iron deficiency anemia (IDA) in patients with ACD [<span>3</span>] and maximizing sensitivity is an important consideration. ROC curves provide a range of potential cutoffs (with a trade-off between sensitivity and specificity). Given the purpose of the index, a cutoff and algorithm were selected which provide high sensitivity. In patients with ACD, a ferritin level below 30 ng/mL is extremely valuable in recognizing iron deficiency. When ferritin levels are greater than 30 ng/mL in patients with ACD, the ferritin level alone is not useful in diagnosing concurrent iron deficiency.</p><p>The authors of the letter to the editor claim that our statement that the TfR index is superior to ferritin alone is false, and question why a ROC curve for ferritin was not reported [<span>4</span>]. They construct an approximate ROC curve derived from our original paper, showing that this curve is virtually superimposed on that for TfR index. A ROC curve was not included in the original manuscript; however, raw data to construct the ROC curve were included in the tables and within the results section of the manuscript. Based on recognized low end ferritin cut-off levels (< 15 or < 30 ng/mL) that clearly indicate the presence of underlying iron deficiency, it was not included. Further and more importantly, ferritin values above 30 ng/mL fall into the established normal range. From a pragmatic standpoint, if a patient's ferritin value is within the normal range, further testing is required if inflammation is present to demonstrate the presence or absence of iron deficiency and thereby to justify iron replacement therapy. Thus, although this approximated ROC curve for ferritin alone appears to overlap with that of the TfR index, further testing would be indicated if ferritin alone was used to correctly assess whether iron deficiency coexists or not. Testing using ferritin alone, as the authors of the letter suggest (based on the ROC curves), would result in many cases of co-existent iron deficiency being missed unless the ferritin level was ≤ 30 ng/mL. This is illustrated by the results in our paper as follows. In patients with ferritin levels between 30 and ","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":"101 12","pages":"3072-3073"},"PeriodicalIF":9.4,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ajh.70511","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149035931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ruixuan Ai, Zhenyu Yang, Guanbang Hong, Yajun Wang
{"title":"What Does “Non-Transfusion-Dependent” Measure in Clinical Trials?","authors":"Ruixuan Ai, Zhenyu Yang, Guanbang Hong, Yajun Wang","doi":"10.1002/ajh.70509","DOIUrl":"10.1002/ajh.70509","url":null,"abstract":"<p>Non-transfusion-dependent thalassemia (NTDT) remains a useful clinical description, but its meaning is more fluid than the name suggests. It identifies patients who do not require lifelong regular red blood cell (RBC) transfusions for survival, while allowing intermittent transfusions and the later emergence of an indication for regular support as anemia or complications evolve [<span>1</span>]. NTDT classification and current transfusion requirement are therefore related but not equivalent. Contemporary care does not infer current transfusion need from a single hemoglobin value or genotype. Symptoms, serial hemoglobin, growth and development, exercise tolerance, extramedullary hematopoiesis, pulmonary hypertension, bone disease, and the response to previous transfusion all contribute to that assessment [<span>1</span>]. Untreated ineffective erythropoiesis and chronic anemia can produce substantial morbidity even when transfusions have been infrequent.</p><p>Drug trials need reproducible entry rules, and transfusion history offers a measure that can be verified. We identified programs through targeted searches of PubMed and ClinicalTrials.gov through August 21, 2026 using thalassemia combined with NTDT, non-transfusion-dependent, or intermedia, and cross-checked the reference lists of recent NTDT reviews. Eligible programs had Phase 2 or 3 prospective pharmacologic results in NTDT or an equivalent low-transfusion thalassemia population. We excluded established supportive therapies and nonpharmacologic studies and, for each independent development program, retained the Phase 2 or 3 report with the most complete publicly available eligibility criteria. Eight programs met these criteria (Table 1) [<span>2-9</span>]. The look-back period ranged from 8 weeks to 12 months; allowable exposure was reported variously as RBC units, transfusions, or transfusion episodes, with upper limits ranging from none to 6, and several protocols also required a recent transfusion-free interval. These choices were explicit and internally reproducible. In the publicly available criteria, however, historical exposure was not accompanied by a separate standardized characterization of the participants' current clinical and biological phenotype, including anemia severity over time, anemia-related morbidity, and whether regular transfusion was clinically recommended at enrollment. Historical exposure therefore provided a reproducible eligibility measure but did not, on its own, fully characterize the phenotype entering the trial.</p><p>The baseline data illustrate why this distinction matters. In BEYOND, 125 (86.2%) of 145 participants had received no RBC units during the 24 weeks before randomization. Median baseline hemoglobin was 8.2 g/dL (IQR, 7.3–9.2), and the report described a post hoc analysis excluding participants with baseline values of 5–7 g/dL [<span>5</span>]. In ENERGIZE, 168 (86.6%) of 194 participants had received no RBC transfusion during the same interv","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":"101 12","pages":"3074-3076"},"PeriodicalIF":9.4,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ajh.70509","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149048825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Hairy Cell Leukemia: 2026 Update on Diagnosis, Risk-Stratification, and Treatment","authors":"Xavier Troussard, Elsa Maître, Jérôme Paillassa","doi":"10.1002/ajh.70441","DOIUrl":"10.1002/ajh.70441","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Disease Overview</h3>\u0000 \u0000 <p>Hairy cell leukemia (HCL) and HCL-like disorders, including HCL variant (HCL-V) and splenic diffuse red pulp lymphoma (SDRPL), are a very heterogeneous group of mature lymphoid B-cell disorders characterized by the identification of hairy cells, a specific immunophenotypic and genetic profile, a different clinical course and the need for appropriate treatment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Diagnosis</h3>\u0000 \u0000 <p>Diagnosis of HCL is based on morphological evidence of hairy cells, characteristic flow cytometric immunophenotype (CD11c, CD103, CD123, CD25) bone marrow trephine biopsy which makes it possible to specify the degree of tumoral bone marrow infiltration and presence of the Annexin A1 marker in immunohistochemistry, and presence of the BRAF<sup>V600E</sup> mutation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Risk Stratification</h3>\u0000 \u0000 <p>Progression of patients with HCL is based on a large splenomegaly, leukocytosis, a high number of hairy cells in the peripheral blood and the unmutated ImmunoGlobulin HeaVy (IGHV) chain variable region gene mutational status. VH4-34 positive HCL cases are associated with a poor prognosis, as well as the rare cases of HCL with <i>TP53</i> mutations and HCL-V.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Treatment</h3>\u0000 \u0000 <p>Patients should be treated only if HCL is symptomatic. Chemotherapy with purine analogs (PNAs) are indicated in first-line HCL patients. The use of chemo-immunotherapy combining cladribine (CDA) and rituximab (R) represents an increasingly used therapeutic approach. Management of relapsed/refractory disease is based on the use of BRAF inhibitors (BRAFi) plus R, MEK inhibitors (MEKi), Bruton Tyrosine Kinase inhibitors (BTKi) and/or Bcl-2 inhibitors (Bcl-2i). The optimal sequence of the different treatments remains to be determined.</p>\u0000 </section>\u0000 </div>","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":"101 12","pages":"3010-3031"},"PeriodicalIF":9.4,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ajh.70441","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148966180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}